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Diagnostic criteria of organ failure 
Diagnostic criteria of organ failure were based on the CLIF-C organ failure score (1): 
Liver failure: serum bilirubin ≥12 mg/dl; Renal failure: serum creatinine ≥2 mg/dl; 
Cerebral failure: Grade III-IV hepatic encephalopathy (West-Haven classification) (2); 
Coagulation failure: INR ≥2.5; Circulatory failure: use of vasoconstrictors to treat 
severe arterial hypotension (use of vasoconstrictors for the treatment of type-1 
hepatorenal syndrome not included); Respiratory failure: PaO2/FiO2 ≥214 or 
SpO2/FiO2 ≥200. Renal dysfunction was diagnosed in patients with serum creatinine 
values between 1.5 and 1.9 mg/dL. Cerebral dysfunction was diagnosed in patients 
with Grade I-II encephalopathy (3). Type 1 ACLF defines the presence of (a) renal 
failure alone; (b) liver, coagulation or respiratory failure alone when associated with 
renal and/or cerebral dysfunction; (c) cerebral failure alone when associated with 
renal dysfunction (3).  Single non-renal organ failure without cerebral and/or renal 
dysfunction was, therefore, not considered as ACLF-1. Type 2 and Type 3 ACLF 
define the presence of 2 and 3 to 6 organ failures, respectively (3).  
 
Supplementary methods 
Measurement of plasma cytokines 
Cytokine levels were determined in 25l of plasma using a multiplexed bead-based 
immunoassay (Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel 
(Merck Millipore, Darmstadt, Germany)) on a Luminex 100 Bioanalyzer (Luminex 
Corp., Austin, TX). The readouts were analyzed with the standard version of the 
Milliplex Analyst software (Merck Millipore). A five-parameter logistic regression 
model was used to create standard curves (pg/mL) and to calculate the concentration 
of each sample. The intra-assay and inter-assay coefficients of variation are 
indicated in Supplementary Table 1.  
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The main biological effects of the cytokines included in the main analysis are 
described in Supplementary Table 4 (4-19). 
 
Criteria used to select the redox state of albumin as marker of systemic inflammation 
and methods of measurement of albumin oxidation.  
The redox state of albumin was selected as marker of systemic inflammation 
because in our experience (Öttle and Stauber, unpublished observations) it does not 
require sample preparation and is stable for more than 2 years in samples obtained 
in EDTA tubes and kept at -70ºC. Other biomarkers of systemic oxidative stress 
(isoprostanes, myeloperoxidase, malondialdehyde, nitrotyroxine and total antioxidant 
capacity) require sample preparation prior to storage, are influenced by storage 
and/or time to analysis or have not been studied regarding long-term stability (20-22).   
The methodology used was as follows: albumin oxidation fractions were separated 
by high performance liquid chromatography (HPLC) and detected by fluorescence. 
Briefly, plasma was diluted 1:100 to a final volume of 1 ml in sample-buffer (0.1 M 
sodium phosphate, 0.3 M sodium chloride, pH 6.87) and filtered through a Whatman 
0.45 µm nylon filter (Bartelt Labor-&Datentechnik, Graz, Austria). Twenty µL of the 
filtrate were injected into a high performance liquid chromatography (HPLC) system 
and separated on a Shodex Asahipak ES-502N 7C anion exchange column (7.5 x 
100 mm, Bartelt Labor-&Datentechnik) with 50 mM sodium acetate, 400 mM sodium 
sulfate, pH 4.85 as the mobile phase. For elution, a gradient of 0 to 6% ethanol and a 
flow rate of 1 ml/min were used. The column was kept at 35°C. Detection was carried 
out by fluorescence at 280/340 nm. Quantification was based on the area of the 
individual peaks as determined by fitting Gaussian functions to the peaks using the 




Criteria used to select plasma renin concentration (PRC) and plasma copeptin 
concentration (PCC) as markers of systemic circulatory dysfunction (SCD) and 
methods of measurements.  
PRC and PCC were selected to estimate systemic circulatory function because they 
are very sensitive to changes in effective arterial blood volume in cirrhosis (23,24). 
Other measurements estimating systemic circulatory function (ADH, renin activity and 
plasma neuropeptide Y) were not considered because they are affected by long-term 
storage (25,26). Plasma norepinephrine was not considered because it is frequently 
used in the management of patients with ACLF.  
PRC was measured using the chemiluminescent immunoassay Liaison Direct Renin 
(DiaSorin; Saluggia, Italy). The test was performed on the LIAISON Analyzer 
(DiaSorin). The intra-assay and inter-assay coefficients of variation were <5% and 
<7%, respectively, for all the samples tested. PCC was measured using an 
immunoassay in a chemiluminescence-coated tube format (B.R.A.H.M.S., Kryptor, 
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Supplementary Figure Legends 
 
Supplementary Figure 1: Pro-inflammatory/anti-inflammatory ratios as estimated by 
interleukin-6 (IL-6)/IL-10 and IL-8/IL-10 ratios in healthy subjects, patients with 
decompensated cirrhosis without acute-on-chronic liver failure (ACLF) and in patients 
with decompensated cirrhosis with ACLF. Data are mean ± SEM and P values are 
given as compared to healthy subjects.  
Supplementary Figure 2: Upper Panel). Scatter graph of individual patients 
classified by the presence (red dots) or absence (green dots) of acute-on-chronic 
liver failure (ACLF) according to individual values of plasma renin concentration 
(PRC) and interleukin-6 (IL-6). The cut-off points for each marker divide the whole 
cohort into 3 tertiles (T1: lower values; T2: intermediate values; T3: higher values). 
Patients with hepatorenal syndrome (HRS) were predominantly in the right part of the 
panel. Lower Panel: Frequency of ACLF across the three tertiles of both PRC and IL-
6.   
Supplementary Figure 3: Upper Panels (A and B). Scatter plots of patients without 
active alcoholism and with (red dots) or without (green dots) acute-on-chronic liver 
failure (ACLF) according to individual values of plasma renin concentration (PRC) 
and interleukin-8 (IL-8) (left) or human nonmercaptalbumin-2 (HNA2) (right). Two cut-
off points for each marker divide each cohort into 3 tertiles (T1: lower values; T2: 
intermediate values; T3: higher values). Patients with ACLF are predominantly in the 
right part of the panels (higher degree of SI). Lower Panels (C and D) show the 
presence of ACLF within each tertile of both PRC and IL-8 and PRC and HNA2. 
Supplementary Figure 4: Upper Panels (A and B). Scatter plots of patients with (red 
dots) or without (green dots) acute-on-chronic liver failure (ACLF) with renal failure 
(ACLF-RF) according to individual values of plasma renin concentration (PRC), 
interleukin-8 (IL-8) (left) or human nonmercaptalbumin-2 (HNA2) (right). Two cut-off 
points for each marker divide each cohort into 3 tertiles (T1: lower values; T2: 
intermediate values; T3: higher values). Patients with ACLF-RF are predominantly in 
the right part of the panels (higher degree of SI). Lower Panels (C and D) show the 




Supplementary Figure 5: Scatter plots of individual values of plasma renin 
concentration (PRC), interleukin-8 (IL-8), interleukin-6 (IL-6) and human 
nonmercaptalbumin-2 (HNA2) in patients with ACLF without active alcoholism (A) 
and with acute-on-chronic liver failure (ACLF) associated with renal failure without 
active alcoholism (B). Horizontal lines represent the upper normal limits (95% 
percentile of the distribution of values in healthy subjects). 
Supplementary Figure 6: Upper Panels (A and B). Scatter plots of patients who died 
(red dots) or survived (green dots) at 90 days after enrolment according to individual 
values of plasma renin concentration (PRC) and interleukin-8 (IL-8) (left) or human 
nonmercaptalbumin-2 (HNA2) (right). Two cut-off points for each marker divide each 
cohort into 3 tertiles (T1: lower values; T2: intermediate values; T3: higher values). 
Patients who died are predominantly in the right part of the panels (higher degree of 
SI). Lower Panels (C and D) show the 90-day mortality within each tertile of both 





Supplementary Table 1: Intra-assay and inter-assay coefficients of variability (CV) of the 
29-cytokine assay.  
 
 
Intra-assay precision was obtained from the mean of the % CV’s from sixteen reportable results across two 
different concentrations of cytokines in a single assay. Inter-assay precision was obtained from the mean of the 




 Intra-assay %CV Inter-assay %CV  
IFNα2  2.4 13.3 
IL-12P40  2.8 12.4 
IL-12P70   2.2 16.7 
IL-13   2.2 9.2 
IL-15   2.7 8.1 
IL-1α   3.3 12.8 
IL-1β   2.3 6.7 
IL-2   2.1 6.3 
IL-3   3.4 6.1 
IL-4   2.9 14.2 
IL-5   2.6 10.8 
MIP-1α   1.9 14.5 
TNFβ   1.6 11.4 
EGF   2.3 5.8 
VEGF   3.7 10.4 
TNF  2.6 13.0 
IL-6   2.0 18.3 
IL-8   1.9 3.5 
MCP-1   1.5 7.9 
IP-10   2.6 15.3 
MIP-1   2.4 8.8 
G-CSF   1.8 15.5 
GM-CSF   3.1 10.1 
IL-10   1.6 16.8 
IL-1ra  2.1 10.7 
IFN   1.6 12.0 
Eotaxin   7.2 10.8 
IL-17a   2.2 7.9 




Supplementary Table 2. Limit of detection for each cytokine included in the study and 
percentage of samples with undetectable levels. 
* The lower limit of detection was calculated………..  









Cirrhotic patients  
with ACLF  
(n=237) 
Cytokines with undetectable levels in less than 30% of samples: 
  TNF  0.7 0 0 0 
  IL-6  0.3 87.5% 7.4% 0.8% 
  IL-8  0.4 10.0% 0 0 
  MCP-1  1.9 0 0 0 
  IP-10  8.6 0 0 0.4% 
  MIP-1  3.0 0 0.7% 0 
   G-CSF  1.8 20.0% 2.5% 0.8% 
GM-CSF  7.5 85.0% 4.2% 3.0% 
   IL-10  1.1 60.0% 5.6% 7.6% 
   IL-1ra 8.3 7.5% 0 0.8% 
   IFN  0.8 40.0% 0 1.3% 
   Eotaxin  4.0 17.5% 0.7% 0.4% 
   IL-17a  0.7 52.5% 1.1% 0.4% 
   IL-7  1.4 80.0% 9.1% 9.3% 
EGF 2.8 17.5% 27.0% 31.6% 
VEGF  26.3 65.0% 22.8% 16.9% 
IFNα2  2.9 87.5% 19.3% 12.2% 
Cytokines  with undetectable levels in more than 30% of samples: 
  IL-12P40  7.4 87.5% 71.2% 65.8% 
  IL-12P70  0.6 65.0% 66.3% 55.7% 
  IL-13  1.3 90.0% 83.5% 77.2% 
  IL-15  1.2 92.5% 70.2% 42.2% 
  IL-1α  9.4 72.5% 44.2% 30.4% 
  IL-1β  0.8 90.0% 83.2% 81.9% 
  IL-2  1.0 82.5% 74.4% 70.9% 
  IL-3 0.7 80.0% 96.8% 97.0% 
  IL-4  4.5 97.5% 77.9% 75.5% 
  IL-5  0.5 22.5% 81.1% 81.4% 
  MIP-1α  2.9 82.5% 34.7% 26.6% 
  TNFβ  1.5 85.0% 78.6% 73.8% 
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 Supplementary Table 3. Patients’ characteristics. 




ACLF – I 
N=126 
ACLF – II 
N=86 
ACLF – III 
N=25 
      
Age (y) 57±12 57±11 59±11 55±11 53±10* 
Gender(Male) 191(67.0) 153(64.6) 85(67.5) 55(64.0) 13(52.0) 
      
Etiology      
     Alcohol 128(47.6) 128(57.7)* 67(58.3) 49(59.0) 12(50.0) 
     HCV 66(24.5) 41(18.5) 22(19.1) 16(19.3) 3(12.5) 
     Alcohol + HCV 26(9.7) 23(10.4) 11(9.6) 9(10.8) 3(12.5) 
      
Time from previous decompensation      
    No previous decompensation 83(31.7) 53(25.6) 22(20.2) 25(32.9) 6(27.3)* 
    Less than 3 months 21(8.0) 30(14.5) 16(14.7) 7(9.2) 7(31.8) 
    More than 3 months 158(60.3) 124(59.9) 71(65.1) 44(57.9) 9(40.9) 
      
Clinical Features      
     Ascites1 211(74.0) 226(95.4)^ 119(94.4) 83(96.5) 24(96.0) 
     Gastrointestinal hemorrhage 54(19.0) 31(13.1) 13(10.3) 15(17.4) 3(12.0) 
     Mean Arterial Pressure (mm Hg) 84±12 81±13* 82±13 81±13 75±11* 
     SIRS 31 (10.9) 47 (19.9)* 17 (13.5) 20 (23.3) 10 (41.7)^ 
Potential precipitating events (PE)      
     Bacterial Infection 61(21.4) 80(34.2)* 38(30.7) 29(34.1) 13(52.0) 
     Active alcoholism within the past  
     3 months 
33(12.5) 39(17.8) 14(12.1) 19(24.4) 6(24.0) 
     Acute Alcoholic Hepatitis 18 (6.3) 29 (12.2)* 11 (8.7) 14 (16.3) 4 (16.0) 
     Other PE2 16(5.6) 28(11.8)* 12(9.5) 14(16.3) 2(8.0) 
     No PE 131(48.5) 94(41.8) 57(47.5) 29(36.3) 8(32.0) 
     More than one PE 27(10.0) 37(16.4)* 17(14.2) 16(20.0) 4(16.0) 
      
Laboratory data      
     WBC (x109/L)3 6.1(4.1-9.0) 7.9(5.3-11.8)^ 7.1(5.0-10.2) 9.5(5.8-13.7) 11.2(5.7-19.0)^ 
     Serum bilirubin (mg/dL)3 3.0(1.6-6.7) 6.0(2.1-14.5)^ 2.9(1.4-8.4) 10.6(4.8-19.7) 24.4(5.8-30.0)^ 
     INR3 1.5(1.3-1.7) 1.8(1.4-2.3)^ 1.5(1.3-1.9) 2.0(1.6-2.6) 2.5(1.9-3.5)^ 
     Serum creatinine (mg/dL)3 0.9(0.7-1.3) 1.7(0.9-2.7)^ 1.9(1.1-2.9) 1.1(0.8-2.2) 1.9(1.1-3.4)* 
     Albumin (g/dL) 2.9±0.6 2.8±0.7 3.0±0.6 2.7±0.7 2.6±0.7* 
     C-reactive protein (mg/L)3 18 (6-35) 27 (12-20)* 33 (19-62) 18 (4-30) 51 (31-69) * 
     Platelet count (x109/L)3 87(57-139) 78(52-120) 84(55-141) 75(53-113) 64(30-104) 
     Sodium (mmol/L) 136±5 133±7^ 134±7 133±6 134±10 
     IgG (g/L) 3 16 (12-20) 15 (11-18) 14 (11-17) 16 (11-19) 17 (15-19) 
     IgA (g/L) 3 4.7 (3.0-6.6) 5.1 (3.3-8.0) 4.8 (2.7-6.1) 6.8 (3.4-8.8) 5.1 (3.9-9.1) 
     IgM (g/L) 3 1.4 (0.9-2.1) 1.2 (0.8-2.2) 1.1 (0.6-1.8) 1.4 (0.8-2.6) 2.3 (0.9-3.1) 
      
Organ failures/dysfunction      
     Liver 31(10.9) 79(33.3)^ 22(17.5) 41(47.7) 16(64.0)^ 
     Kidney - 104(43.9) 61(48.4) 28(32.6) 15(60.0)* 
     Cerebral 6(2.1) 37(15.6)^ 5(4.0) 21(24.4) 11(44.0)^ 
     Coagulation 10(3.5) 46(19.4)^ 8(6.4) 26(30.2) 12(48.0)^ 
     Circulation 3(1.1) 31(13.1)^ 2(1.6) 15(17.4) 14(56.0)^ 
     Lungs 2(0.7) 15(6.3)^ 4(3.2) 6(7.0) 5(20.0)* 
Kidney dysfunction 51(17.9) 30(12.7) 17(13.5) 9(10.5) 4(16.0) 
Mild to moderate hepatic   
encephalopathy 
69(24.3) 86(36.3)* 55(43.7) 21(24.4) 10(40.0)* 
      
Scores      
     Child-Pugh 9.1±1.9 10.7±2.1^ 9.7±1.9 11.5±1.8 12.4±1.8^ 
     MELD 17±5 25±7^ 23±6 27±7 32±8^ 
     MELDna 19±6 27±7^ 25±6 29±7 33±7^ 
     CLIF-C OF 7.1±1.1 9.6±2.3^ 8.4±1.3 10.0±1.8 12.5±3.3^ 
      
Mortality rates (%)      
     28 days 6(2.1) 65(27.4)^ 26(20.6) 22(25.6) 17(68.0)^ 
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     90 days 29(10.3) 99(42.5)^ 41(33.6) 40(46.5) 18(72.0)* 
    180 days 45(16.4) 122(52.8)^ 57(47.1) 46(54.1) 19(76.0)* 
    365 days 74(35.9) 143(70.1)^ 73(67.0) 50(69.4) 20(87.0) 
      
1Diagnosed by the presence of clinically detectable ascites at enrolment or of surrogates of ascites (diuretic 
treatment, SBP, therapeutic paracentesis prior to or after enrolment). 
2Other precipitating event (PE) was defined by the presence prior to or at enrolment of one of the 
following: transjugular intrahepatic portosystemic shunting, major surgery, therapeutic paracentesis 
without use of intravenous albumin or hepatitis. 
3Data are median (IQR). Comparison between NO ACLF vs ACLF and among grades of ACLF: *p-value < 0.05; 





Supplementary Table 4: Predominant biological properties of the 17 cytokines with detectable values in more than 70% of samples. 
Gene 
symbol* 
Protein name** Protein short 
name** 







TNF TNF superfamily Neutrophils, macrophages, 
monocytes, endothelial cells 
Innate immune response and inducer of local and 
systemic inflammation; promotes activation and 
production of acute-phase proteins 
4 
IL6 Interleukin-6 IL-6 Hematopoietin Wide variety of cells: B cells, T 
cells, thymocytes, myeloid cells, 
osteoclasts 
Inflammatory and co-stimulatory action; induces 
proliferation and differentiation; synergizes with TGF-β 
to drive Th17; promotes activation and production of 
acute-phase proteins 
5 
CXCL8 Interleukin-8 IL-8 Chemokine, CXC 
subfamily 
Neutrophils, monocytes, mast 
cells 
Proinflammatory mediator, chemotactic factor for 
neutrophils, induces respiratory burst and phagocytosis.  
6 
CCL2 C-C motif 
chemokine 2 
MCP-1 Chemokine, CC 
subfamily 
Monocytes, basophils, memory 
T cells, pDC 
Pro-inflammatory; chemotactic activity for monocytes 
and basophils  
7 
CXCL10 C-X-C motif 
chemokine 10 
IP-10 Chemokine, CXC 
subfamily 
Monocytes, NK and T-cells Inflammatory chemokine, associated with hepatitis C 
virus and autoimmunity; induced by interferons 
8 
CCL4 C-C motif 
chemokine 4 
MIP-1- Chemokine, CC 
subfamily 
Immature mDC, monocytes, 
Th1, Treg, NK cells, pDC 
Chemokine with chemotactic properties for monocytes 













GM-CSF Hematopoietin Committed progenitors Differentiation and activation of granulocytes and 
monocytes 
11 
IL10 Interleukin-10 IL-10 IL-10 family Macrophages, T cells, dendritic 
cells, B cells 
Immune suppression; decreases antigen presentation 
and MHC class II expression of dendritic cells; down-





IL-1ra IL-1 family  Cells, monocytes and 
endothelial cells 
IL-1ra and the soluble decoy receptor complex 
(composed of IL1R2 and IL1RAP) inhibit IL-1-mediated 
inflammatory responses 
13 
IFNG Interferon gamma IFNγ Interferon family; 
type 2 
Macrophages, NK cells, T cells, 
others 
Promotes activation of APCs and cell-mediated 




IFNA2 Interferon alpha 2 IFNα2 Interferon family; 
type 1  
NK cells, many others Promotes resistance to viral pathogens; promotes 
increased expression of MHC class I; involved in auto-
immunity 
14 
CCL11 Chemokine (C-C 
Motif) Ligand 11 
Eotaxin Chemokine, CC 
subfamily 
Eosinophils Chemotactic factor mainly involved in eosinophil 
recruitment and allergic responses. 
15 
IL17A Interleukin-17A IL-17a IL-17 family Mucosal tissues, epithelial and 
endothelial cells 
Proinflammatory; protective immunity in lung; tight 
junction integrity; promotes mobilization of neutrophils 
and cytokine production by epithelial cells; promotes 
angiogenesis 
16 
IL7 Interleukin-7 IL-7 Hepatopoietin B cells, T cells, thymocytes Homeostasis, differentiation, and survival (in particular 




EGF EGF family Wide variety of cells Epithelial cell growth. Stimulates cytokine release. 18 
VEGFA Vascular 
Endothelial 
Growth Factor A 
VEGF-A PDGF family, VEGF 
subfamily 
Endothelial cells Angiogenesis and vascular permeability. Leukocyte 
adhesion. 
19 
*From Hugo Gene Nomenclature Committee 
**From UniProt (http://www.uniprot.org/) 
***Abbreviations: TGFβ, transforming growth factor-β; Th17, IL-17-producing helper T cells; Th1, T helper 1 cells; Th2, T helper 2 cells; pDC, plasmacytoid 




Supplementary Table 5. Plasma concentrations (pg/mL) of the cytokines with detectable values in less 
than 70% of patients. Relationship with the presence of ACLF.   
Cytokines  
(number of subjects with data) 
Healthy controls No ACLF ACLF 
p-
value* 
Pro-inflammatory Cytokines     
  IL-1α  (11/159/165) 9.1 (1.8-56.3) 31.9 (5.7-111.8) 20.5 (7.4-81.2) 0.5751 
  IL-1β  (4/48/43) 3.3 (1.2-4.0) 8.8 (4.1-28.9) 6.7 (3.7-12.7) 0.2554 
  IL-12P40 (5/82/81) 12.7 (5.0-31.1) 29.4 (8.5-86.6) 29.6 (14.5-72.7) 0.8050 
  IL-12P70  (14/96/105) 1.9 (0.5-5.5) 9.8 (4.8-34.3) 9.6 (4.9-29.4) 0.5470 
  MIP-1α  (7/186/174) 0.81 (0.18-2.52) 4.7 (1.8-9.8) 7.1 (3.4-15.5) 0.0006 
  TNFβ  (6/61/62) 5.2 (0.1-22.5) 12.2 (2.0-9.5) 4.9 (2.7-22.6) 0.0718 
Anti-inflammatory Cytokines     
  IL-13  (4/47/54) 14.0 (2.2-26.2) 37.9 (7.3) 16.0 (5.2-65.8) 0.1068 
  IL-4  (1/63/58) 13.2 16.9 (6.4-82.0) 19.0 (6.9-46.0) 0.8643 
Other Cytokines     
  IL-2  (7/73/69) 0.5 (0.3-5.6) 5.5 (2.6-16.7) 4.6 (2.1-9.1) 0.5672 
  IL-3  (8/9/7) 0.06 (0.02-0.15) 4.3 (2.5-8.7) 4.7 (2.5-13.6) 0.9578 
  IL-5  (31/54/44) 0.34 (0.20-0.58) 4.3 (2.5-8.7) 4.9 (3.0-9.1) 0.3079 
  IL-15  (3/85/137) 1.6 (1.0-1.6) 5.8 (3.3-13.0) 6.1 (3.7-9.6) 0.8805 
Data are median (Inter-Quartile Range, IQR) 
*P value between ACLF and NO ACLF. 
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 Supplementary Table 6. Plasma levels of the cytokines (pg/mL) with detectable values in less than 
70% of patients. Relationship with the ACLF grades.   
 
Cytokines 
(number of patients with data) 
ACLF – I ACLF – II ACLF – III 
 
p-value* 
Pro-inflammatory Cytokines     
  IL-1α  (87/59/19) 21.7 (8.2-96.3) 21.9 (6.6-85.6) 11.3 (8.8-27.3) 0.4129 
  IL-1β  (23/17/3) 7.6 (3.5-12.7) 6.9 (3.7-19.3) 3.7 (3.6-5.5) 0.4088 
  IL-12P40  (43/30/8) 28.9 (14.3-51.4) 37.2 (16.1-159.7) 36.3 (5.3-104.9) 0.6347 
  IL-12P70  (52/41/12) 8.1 (4.7-21.2) 14.2 (6.5-38.5) 6.6 (3.7-20.6) 0.1629 
  MIP-1α  (93/62/19) 7.6 (3.4-12.0) 6.3 (3.1-15.5) 8.6 (4.0-22.0) 0.4819 
  TNFβ  (33/25/4) 3.6 (2.7-18.0) 8.0 (2.9-26.5) 7.5 (2.8-86.2) 0.4988 
Anti-inflammatory Cytokines     
  IL-4  (29/23/6) 16.5 (6.6-28.4) 26.9 (6.0-96.3) 18.8 (10.0-45.1) 0.4586 
  IL-13  (26/24/4) 10.8 (5.2-40.4) 27.4 (7.1-85.2) 15.0 (7.8-200.5) 0.2651 
Other Cytokines     
  IL-2  (36/26/7) 4.2 (1.9-8.1) 5.8 (3.4-14.5) 3.2 (1.8-8.4) 0.2187 
  IL-3 (3/4/0) 4.0 (2.5-4.7) 13.4 (7.8-22.6) --- 0.4108 
  IL-5  (23/19/2) 4.3 (2.8-8.0) 5.8 (3.2-11.1) 51.4 (3.4-99.5) 0.5309 
Data are median (Inter-Quartile Range, IQR) 





Supplementary Table 7. Markers of systemic circulatory dysfunction (SCD), plasma cytokine levels 
and redox state of albumin in all patients with alcoholic cirrhosis according to the presence of 















Markers of SCD      
   PRC (micro IU/ml) 108 (19-268) 111 (32-274) 84 (25-277) 0.8833 
   PCC (pmol/L) 12 (1-32) 15 (5-36) 16 (5-40) 0.6336 
Pro-inflammatory Cytokines     
   TNF (pg/ml) 19 (14-24) 21 (14-31) 23 (15-35) 0.1613 
   IL-6 (pg/ml) 24 (12-75) 23 (12-44) 29 (16-69) 0.3822 
   IL-8 (pg/ml)  98 (60-181) 199 (113-344) 56 (30-106) <0.0001 
   MCP-1 (pg/ml) 413 (302-635) 500 (354-690) 373 (279-526) 0.0366 
   IP-10 (pg/ml) 1086 (653-1362) 893 (580-1689) 987 (606-1957) 0.7524 
   MIP-1 (pg/ml) 27 (16-50) 35 (24-54) 25 (15-44) 0.0531 
   G-CSF (pg/ml) 32 (24-91) 30 (16-47) 29 (13-70) 0.4161 
   GM-CSF (pg/ml) 6.8 (4.0-13.9) 6.5 (4.0-12.5) 5.9 (2.4-15.5) 0.5596 
Anti-inflammatory Cytokines     
   IL-10 (pg/ml) 2.6 (1.2-5.5) 5.9 (2.2-12.5) 4 (1-19) 0.3676 
   IL-1ra (pg/ml) 18 (9-62) 18 (10-44) 16 (6-58) 0.6236 
Other Cytokines     
   IFN (pg/ml) 16 (4-50) 11 (3-30) 7 (3-29) 0.4725 
IFNα2 (pg/ml) 35 (14-74) 16 (5-33) 116 (78-166) 0.1161 
   Eotaxin (pg/ml) 130 (93-180) 118 (89-197) 6 (2-14) 0.4940 
   IL-17a (pg/ml) 12.3 (3.1-26.0) 6.0 (1.7-23.4) 3 (1-11) 0.2286 
   IL-7 (pg/ml) 2.8 (1.3-12.2) 3.8 (1.8-11.4) 27 (8-70) 0.8507 
EGF (pg/ml) 19 (5-33) 15 (8-47) 26 (8-71) 0.2188 
VEGF (pg/ml) 62 (40-365) 112 (54-276) 99 (35-282) 0.7537 
Albumin Oxidation 
Fractions*** 
    
   HMA (%) 52 (42-70) 49 (34-61) 51 (36-61) 0.5060 
   HNA1 (%) 37.2 (29.5-41.3) 46.9 (34.3-57.3) 41.7 (32.9-54.0) 0.1597 
   HNA2 (%) 9.2 (4.2-11.4) 5.7 (4.2-9.8) 6.5 (3.3-11.0) 0.6939 
 Data are median (Inter-Quartile Range, IQR)  
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Supplementary Table 8. Plasma concentrations of renin (PRC), copeptin (PCC) and cytokines and 




   Patients without SIRS 
                (n=443) 
     Patients with SIRS 
              (n=78) 
p-value 
Markers of SCD     
   PRC (micro IU/ml) 80 (24-277) 101 (32-447) 0.1365 
   PCC (pmol/L) 14 (5-36) 26 (9-45) 0.0126 
Pro-inflammatory Cytokines    
   TNF (pg/ml) 22 (15-33) 27 (17-38) 0.1118 
   IL-6 (pg/ml) 26 (13-53) 61 (20-168) <0.0001 
   IL-8 (pg/ml)  50 (25-104) 96 (38-182) <0.0001 
   MCP-1 (pg/ml) 352 (247-509) 412 (279-756) 0.0193 
   IP-10 (pg/ml) 1036 (606-1917) 1005 (624-2005) 0.7744 
   MIP-1(pg/ml) 24 (14-40) 30 (16-47) 0.0376 
   G-CSF (pg/ml) 25 (13-54) 29 (16-93) 0.0520 
   GM-CSF (pg/ml) 5.5 (2.6-12.5) 6.8 (2.7-16.0) 0.2764 
Anti-inflammatory Cytokines    
   IL-10 (pg/ml) 4.2 (1.4-13.9) 9.2 (2.9-19.8) 0.0077 
   IL-1ra (pg/ml) 14 (6-33) 26 (10-71) 0.0003 
Other Cytokines    
   IFN(pg/ml) 6 (2-21) 6 (3-15) 0.8457 
IFNα2 (pg/ml) 23 (10-61) 28 (10-59) 0.9013 
   Eotaxin (pg/ml) 120 (86-165) 101 (72-150) 0.0594 
   IL-17a (pg/ml) 4.0 (1.6-13.0) 3.0 (1.5-15.2) 0.8516 
   IL-7 (pg/ml) 2.9 (1.2-8.9) 3.5 (1.5-10.1) 0.4890 
EGF (pg/ml) 23 (9-60) 17 (8-45) 0.1950 
VEGF (pg/ml) 87 (28-263) 91 (28-202) 0.7148 
Albumin Oxidation Fractions***    
   HMA (%) 
 
49 (37-60) 51 (40-62) 0.4032 
   HNA1 (%) 41.2 (33.3-52.2) 39.5 (29.7-48.9) 0.1953 
   HNA2 (%) 7.0 (3.4-11.6) 7.7 (3.3-12.4) 0.6424 
Data are median (Inter-Quartile Range, IQR) 
IL6-T1 IL6-T2 IL6-T3 Overall
PRC
PRC-T3
22/48 (46%) 28/54 (52%) 48/68 (71%)
98/170 (58%)*
PRC-T2
20/59 (34%) 25/51 (49%) 29/52 (56%)
74/162 (46%)
PRC-T1









*p<0.05 vs previous tertile; #p<0.01 vs previous tertile
Supplementary Figure 2
*p<0.05 vs previous tertile; #p<0.01 vs previous tertile *p<0.05 vs previous tertile; #p<0.01 vs previous tertile
A B
C D
HNA2-T1 HNA2-T2 HNA2-T3 Overall PRC
PRC-T3 8/25 (32%) 25/53 (47%) 46/63 (73%) 79/141 (56%)*
PRC-T2 9/33 (27%) 23/52 (44%) 24/44 (55%) 56/129 (43%)
PRC-T1 10/61 (16%) 11/42 (26%) 22/30 (73%) 43/133 (32%)
Overall
HNA2











IL8-T1 IL8-T2 IL8-T3 Overall PRC
PRC-T3 15/50 (30%) 23/36 (64%) 41/55 (75%) 79/141 (56%)*
PRC-T2 10/34 (29%) 21/50 (42%) 25/46 (54%) 56/130 (43%)
PRC-T1 9/61 (15%) 13/35 (37%) 23/39 (59%) 45/135 (33%)
Overall
IL-8
34/145 (23%) 57/121 (47%)# 89/140 (64%)# n=406
Supplementary Figure 3
IL8-T1 IL8-T2 IL8-T3 Overall PRC
PRC-T3 12/48 (25%) 20/41 (49%) 34/51 (67%) 66/140 (47%)#
PRC-T2 9/42 (21%) 19/53 (36%) 23/49 (47%) 51/144 (35%)
PRC-T1 7/63 (11%) 9/42 (21%) 18/38 (47%) 34/143 (24%)
Overall
IL-8
28/153 (18%) 48/136 (35%)# 75/138 (54%)# n=427
*p<0.05 vs previous tertile; #p<0.01 vs previous tertile *p<0.05 vs previous tertile; #p<0.01 vs previous tertile
A B
C DHNA2-T1 HNA2-T2 HNA2-T3
PRC-T3 6/29 (21%) 21/50 (42%) 37/57 (65%) 64/136 (47%)
PRC-T2 7/42 (17%) 17/50 (34%) 28/52 (54%) 52/144 (36%)*
PRC-T1 7/77 (9%) 10/39 (26%) 16/24 (67%) 33/140 (24%)
Overall
HNA2














































IL8-T1 IL8-T2 IL8-T3 Overall PRC
PRC-T3 8/52 (15%) 24/56 (43%) 27/64 (42%) 59/172 (34%) *
PRC-T2 5/46 (11%) 11/58 (19%) 22/60 (37%) 38/164 (23%)
PRC-T1 5/65 (8%) 11/53 (21%) 15/50 (30%) 31/168 (19%)
Overall
IL-8
18/163 (11%) 46/167 (28%)# 64/174 (37%) N=504
HNA2-T1 HNA2-T2 HNA2-T3 Overall PRC
PRC-T3 7/33 (21%) 18/60 (30%) 33/75 (44%) 58/168 (35%)
PRC-T2 8/51 (16%) 15/59 (25%) 14/54 (26%) 37/164 (23%)*
PRC-T1 4/82 (5%) 13/46 (28%) 13/36 (36%) 30/164 (18%)
Overall
HNA2
19/166 (5%) 46/165 (14%)# 60/165 (22%)# N=496
*p<0.05 vs previous tertile; #p<0.01 vs previous tertile *p<0.05 vs previous tertile; #p<0.01 vs previous tertile
A B
C D
PRC-T1
PRC-T2
IL-8-T2
PRC.T3
IL-8-T3IL-8-T1
PRC-T1
PRC-T2
HNA2-T2
PRC.T3
HNA2-T3HNA2-T1
Supplementary Figure 6
